Episode 22

full
Published on:

27th Jul 2021

The distinction of drugs vs cosmetics from a regulatory perspective

As more and more companies operating in the pharmaceutical space are moving into cosmetics, the temptation is to think that life will be much easier from a regulatory and compliance perspective.

However, while it is true that pharmaceuticals are more heavily regulated, this does not mean that cosmetics developers can rest on their laurels.

The subtle lines between making marketing claims about cosmetics that are deemed allowable and those crossing the line into drug products can often be blurred. The wrong claims can cause a cosmetic product to be misbranded attracting unwanted attention from the US Food and Drug Administration.

In this podcast with John Bailey and Catherine Bailey from EAS Consulting, we take a look at the various common compliance issues that can arise when jumping the boundary from drugs to cosmetics.

Listen for free

Show artwork for CPhI Podcast Series

About the Podcast

CPhI Podcast Series
Your new monthly pharma soundbite
The CPHI Podcast Series is your new monthly pharma soundbite, bringing you insights from across the global value chain. Through drug discovery and development to manufacturing and delivery, we’ll bring you impactful content to keep you informed on the latest trends, developments, and opportunities in Pharma.

Brought to you by the organisers of the CPhI and Pharmapack exhibitions, the series is an easy way to stay up to date on the issues which matter to your business. Tune in to hear from key industry stakeholders sharing easy-to-digest insights – the CPhI Podcast Series is your trusted voice in pharma.

About your host

Profile picture for Tara Dougal

Tara Dougal